Drug intelligence / Profile preview

digitoxigenin

Development stage: Preclinical
Modality: Small Molecules
Administration: Intravenous (experimental/in Vivo Studies)

Overview

Digitoxigenin is a cardenolide and the aglycone (non-sugar) constituent of digitoxin, derived from the foxglove plant Digitalis purpurea. It acts as a potent inhibitor of Na+/K+ ATPase by binding to the digitalis receptor site with nanomolar potency. This inhibition leads to increased intracellular sodium and calcium concentrations in cardiac cells, resulting in enhanced cardiac contractility (positive inotropic effect) and cardiotonic effects. Digitoxigenin is highly cytotoxic due to its ability to inhibit Na+/K+ ATPase-dependent protein synthesis and has been investigated for potential antitumor activity[1][2].

Other names: cerberigeninechujetinevonogeninthevetigenin

Targets

ATP1A (Sodium/potassium-transporting ATPase)

Beyond the preview

Go deeper on digitoxigenin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on digitoxigenin.

Explore the full profile